In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...